Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,404 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inflammatory Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

NCT01008423
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
62
States / cities
Dothan, Alabama • Mesa, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 22, 2026, 5:32 AM EDT
Active, not recruiting No phase listed Observational

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

NCT02808780
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
16
States / cities
Murrieta, California • Rialto, California • Ventura, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Phase 2 Interventional

AT1001 for the Treatment of COVID-19 Related MIS-C

NCT05022303
View directory record Official record
Conditions
Covid19, Multisystem Inflammatory Syndrome in Children
Interventions
Larazotide Acetate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
1 Month to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Results available

Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea

NCT01872715
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Oracea
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
25 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 22, 2026, 5:32 AM EDT
Completed No phase listed Observational

A Long-term Safety Study of Infliximab (Remicade)

NCT00261976
View directory record Official record
Conditions
Arthritis, Rheumatoid, Crohn Disease, Psoriasis
Interventions
Infliximab (Remicade)
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
Not listed
Enrollment
2,971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

Extension Study of Semapimod 60 mg IV x 3 Days

NCT00741910
View directory record Official record
Conditions
Crohn's Disease
Interventions
Semapimod
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Chicago, Illinois • Great Neck, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Early Phase 1 Interventional

Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

NCT06056596
View directory record Official record
Conditions
Retinal Detachment, Rhegmatogenous Retinal Detachment
Interventions
Lamivudine 300 MG, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

Autologous Stem Cell Transplant for Crohn's Disease

NCT03219359
View directory record Official record
Conditions
Crohn Disease
Interventions
Autologous stem cell transplant, Cyclophosphamide, Thymoglobulin, Methylprednisolone, Vedolizumab
Procedure · Drug
Lead sponsor
Aaron Etra
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Not listed Phase 1 Interventional

A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

NCT05743010
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
APL-1401, Placebo
Drug
Lead sponsor
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Corona, California • Tampa, Florida • Marrero, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 22, 2026, 5:32 AM EDT
Recruiting Early Phase 1 Interventional

68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease

NCT07273188
View directory record Official record
Conditions
Crohn's Disease, Intestinal Fibrosis, Inflamatory Bowel Disease, Intestinal Strictures Related to Crohn´s Disease
Interventions
Ga68-FAPI-46
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Not applicable Interventional

Fecal Microbiota Transplantation for Ulcerative Colitis

NCT01742754
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Fecal Microbiota Transplantation
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Results available

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis: A Pilot Feasibility Study

NCT03340805
View directory record Official record
Conditions
Shock, Septic
Interventions
Lactated Ringer, Normal saline
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers

NCT00805870
View directory record Official record
Conditions
Muscle Damage, Muscle Inflammation
Interventions
Lovaza (omega-3-acid ethyl esters), Wheat Germ Oil
Drug
Lead sponsor
Western Michigan University
Other
Eligibility
18 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Not applicable Interventional

UC Cohort - The Influence of Diet on Gut Microbiotas

NCT04933162
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
High Protein and Low Fiber Diet, Low Protein and High Fiber Diet
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 22, 2026, 5:32 AM EDT
Active, not recruiting No phase listed Observational

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

NCT01848561
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
8,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
169
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 131 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 22, 2026, 5:32 AM EDT
Active, not recruiting Not applicable Interventional

Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System

NCT04770870
View directory record Official record
Conditions
Osteoarthritis Ankle, Post-Traumatic Osteoarthritis of Ankle, Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)
Interventions
Hintermann Series H3 Total Ankle Replacement System
Device
Lead sponsor
DT MedTech, LLC
Industry
Eligibility
21 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Little Rock, Arkansas • Mission Hills, California • Sarasota, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Not listed Early Phase 1 Interventional

Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis

NCT02390726
View directory record Official record
Conditions
Ulcerative Colitis, Active Moderate
Interventions
Fecal Microbiota Transplant, Placebo
Biological
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Naltrexone on Active Crohn's Disease

NCT00663117
View directory record Official record
Conditions
Inflammation, Crohn's Disease
Interventions
Naltrexone-HCl, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 22, 2026, 5:32 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Guselkumab, Golimumab, JNJ-78934804, Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
63
States / cities
Arcadia, California • Coronado, California • Lancaster, California + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Dietary Salt in Rheumatoid Arthritis

NCT03649178
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
salt
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 4 Interventional

Asacol Dosing Study for Active Ulcerative Colitis

NCT00194818
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol (mesalamine)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2008 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension Study of Brazikumab in Crohn's Disease

NCT03961815
View directory record Official record
Conditions
Crohn's Disease, IBD
Interventions
Brazikumab Induction Dose, Brazikumab Maintenance Dose
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Lincoln, California • Clearwater, Florida • Kissimmee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated No phase listed Observational

PET/CT to Predict Response to Infliximab Therapy in Patients With Crohn's Disease

NCT01759017
View directory record Official record
Conditions
Crohn's Disease
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Broccoli Sprout Extract Effects on Allergic Inflammation in the Nose

NCT00882115
View directory record Official record
Conditions
Allergic Airway Disease
Interventions
Broccoli sprout extract (BSE)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 22, 2026, 5:32 AM EDT